Macroeconomic Highlights - The State Council held a meeting on December 5 to discuss further energy conservation and carbon reduction efforts, emphasizing the importance of these initiatives in achieving carbon peak and carbon neutrality goals [1] - The meeting highlighted the need for higher quality and more effective energy conservation and carbon reduction work, enhancing internal motivation and improving market mechanisms [1] Securities Industry - On December 6, the Chairman of the China Securities Regulatory Commission (CSRC), Wu Qing, addressed the eighth member meeting of the China Securities Association, emphasizing the responsibility of the financial sector in national development [2] - Wu Qing indicated that regulatory policies would encourage differentiated supervision, with a focus on loosening capital space and leverage limits for high-quality institutions to improve capital efficiency [2] Insurance Sector - On December 5, the Financial Regulatory Bureau announced adjustments to risk factors for insurance companies, lowering risk factors for long-term holdings of stocks in the CSI 300 index and STAR Market [3] - The new regulations also reduce premium and reserve risk factors for export credit and overseas investment insurance, while requiring insurers to enhance internal controls and strengthen solvency management [3] Gold Reserves - As of November 2025, China's gold reserves reached 74.12 million ounces (approximately 2,305.39 tons), marking an increase of 30,000 ounces (about 0.93 tons) and continuing a streak of 13 consecutive months of gold accumulation [4] Regulatory Developments for Listed Companies - On December 5, the CSRC released a draft for public consultation on the "Regulations on the Supervision and Management of Listed Companies," aimed at enhancing corporate governance, information disclosure, and investor protection [5] - This draft represents the first specialized administrative regulation for the supervision of listed companies in China [5] Pharmaceutical Sector - The 2025 National Medical Insurance Drug List and the first version of the commercial insurance innovative drug list were released, adding 114 new drugs, including 50 innovative drugs, with an overall success rate of 88%, up from 76% in 2024 [6] - The new lists include advanced treatments such as CAR-T and T-cell therapies, as well as drugs for rare diseases that are not currently covered by basic medical insurance [6] Company News - Muxi Co., Ltd. reported a final online issuance success rate of 0.03348913% [10] - China Pacific Insurance's Vice President Yu Ze is under investigation for serious violations of discipline and law [10] - Guolian Aviation's controlling shareholder and chairman Wang Zengduo has been released from detention [10] - Annie Co., Ltd. is planning a change in control, with stock resuming trading on December 8 [10] - ST Tianrui has terminated plans for a change in control, with stock resuming trading on December 8 [10] - Several pharmaceutical companies, including Heng Rui Medicine and Junshi Bioscience, have successfully added multiple drugs to the national medical insurance directory [10]

Group 1: Healthcare and Pharmaceuticals - A total of 114 new drugs have been added to the 2025 National Medical Insurance Drug List, including 50 Class 1 innovative drugs, enhancing coverage for critical areas such as cancer, chronic diseases, mental illnesses, rare diseases, and pediatric medications [1][2] - Notable companies like Heng Rui Medicine and Fosun Pharma have announced that their products have been included in the new medical insurance directory [1][3][4] - The new commercial health insurance innovative drug directory includes 19 drugs, featuring treatments for cancer and rare diseases, involving companies such as BeiHai KangCheng and WuXi AppTec [2] Group 2: Company Announcements - Guo Ao Technology announced a potential change in control, leading to a temporary suspension of its stock from December 8 [6] - Mu Xi Co., Ltd. reported a final online issuance success rate of 0.03348913% due to a high subscription rate of approximately 4498.38 times [6][7] - An announcement from Baidu Group indicated that the company is evaluating a potential spin-off of its subsidiary Kunlun Chip for independent listing, subject to regulatory approval [12]

Core Insights - The National Healthcare Security Administration (NHSA) has officially announced the latest version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, which includes 114 new drugs and 19 drugs in the first version of the Commercial Health Insurance Innovative Drug Catalog, effective from January 1, 2026 [1][2][3] Industry Summary - The NHSA has adjusted the drug catalog for the eighth time since its establishment, with a total of 949 new drugs added over the years, and the medical insurance fund has spent over 4.6 trillion RMB on negotiated drugs, driving sales exceeding 6 trillion RMB [1][2] - The new catalog includes 50 first-class innovative drugs, with an overall success rate of 88%, significantly higher than the 76% in 2024 [3] - The inclusion of drugs for major diseases such as triple-negative breast cancer, pancreatic cancer, and lung cancer, as well as rare diseases and chronic conditions, addresses gaps in basic medical insurance coverage [2][3] Company-Specific Updates - Green Leaf Pharmaceutical has successfully included five new products in the NHSA's drug catalog, including MiMeiXin® and ZhanBiJia® [4] - Fuhong Hanlin announced that its product Fuzhuoning® has been included in the NHSA's drug catalog for specific indications [5] - Junshi Biosciences reported that its products Tuoyi® and Junshida® have been successfully included in the NHSA's drug catalog [6] - Innovent Biologics has successfully added seven innovative products to the new NHSA drug catalog, including Daboru® and Xindimian® [6]

Core Points - The National Healthcare Security Administration announced the 2025 National Medical Insurance Drug List, which will take effect on January 1, 2026, adding 114 new drugs, including 50 innovative drugs, while removing 29 drugs that are either unavailable or can be replaced by better alternatives [2][4] Group 1: Drug List Adjustments - The total number of drugs in the directory has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines, with significant improvements in coverage for key areas such as cancer, chronic diseases, mental illnesses, rare diseases, and pediatric medications [2][4] - The 2025 adjustment marks the 8th update since the establishment of the National Healthcare Security Administration [7] Group 2: Company Announcements - 15 A-share pharmaceutical companies announced that their products have been included in the new directory, with many innovative drug companies benefiting from this inclusion [4] - Zai Lab's drug, Jikaxitinib, has been included in the directory, which is expected to enhance sales and improve patient accessibility [4] - Junshi Biosciences reported that its products, including Toripalimab and an additional indication for another drug, have been successfully included in the directory [4] - Innovent Biologics' drug, IBI301, has also been added to the new directory, marking a significant milestone for the company [5] - Leading A-share pharmaceutical companies like Fosun Pharma, East China Pharmaceutical, and Heng Rui Medicine have also had several products included, with Heng Rui reporting a combined sales figure of approximately 8.66 billion yuan for the newly added drugs in 2024 [6][7]

Core Viewpoint - Shanghai Junshi Biosciences Co., Ltd. has successfully included two of its products, Toripalimab Injection (brand name: Tuoyi) and Engrelistat Injection (brand name: Junshida), in the National Medical Insurance Catalog (2025) under Category B, effective from January 1, 2026 [1][2]. Group 1: Product Information - Toripalimab Injection is the first domestically approved PD-1 monoclonal antibody in China, with 12 indications approved for listing in the National Medical Insurance Catalog, including treatments for renal cancer, triple-negative breast cancer, and melanoma [2][4]. - Engrelistat Injection is a domestically developed PCSK9-targeting drug, newly included in the National Medical Insurance Catalog, specifically for patients intolerant to statins [5][6]. Group 2: Market Impact - The inclusion of these products in the National Medical Insurance Catalog reflects the recognition of their clinical value and innovation by the National Healthcare Security Administration, which supports local innovative pharmaceutical companies [6]. - The listing of all commercialized products in the National Medical Insurance Catalog is expected to enhance affordability and accessibility for patients, thereby promoting market expansion and increasing sales scale for the company [6].

Core Viewpoint - Shanghai Junshi Biosciences Co., Ltd. announced the inclusion of its products Tuoyi (Tremelimumab injection) and Junshida (Angrezi monoclonal antibody injection) in the National Medical Insurance Directory, effective January 1, 2026, highlighting the recognition of their clinical value and innovation by the National Healthcare Security Administration [1][6]. Group 1: Product Information - Tuoyi (Tremelimumab injection) has received approval for 12 indications, all of which are now included in the National Medical Insurance Directory, making it the only PD-1 monoclonal antibody drug listed for the treatment of renal cancer, triple-negative breast cancer, and melanoma [1][2]. - Junshida (Angrezi monoclonal antibody injection) is the only domestic PCSK9-targeted drug included in the new insurance directory for patients intolerant to statins, marking its first inclusion [1][5]. Group 2: Market Impact - The inclusion of both drugs in the National Medical Insurance Directory is expected to enhance patient affordability and accessibility, thereby promoting market expansion and increasing sales scale for the company [6]. - The company plans to actively cooperate with the implementation of insurance policies and expand its market coverage to improve patient access to medications [6]. Group 3: Internationalization - Tuoyi has been approved for marketing in multiple countries and regions, including the United States, European Union, and several others, indicating a strong international presence [3].

Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have released the updated National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the Commercial Health Insurance Innovative Drug Catalog for 2025, which includes 114 new drugs, 50 of which are Class 1 innovative drugs [1] - The total number of drugs in the National Medical Insurance Drug Catalog will increase to 3,253, with significant improvements in coverage for key areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [1] - The introduction of the Commercial Health Insurance Innovative Drug Catalog is expected to alleviate payment challenges for high-value innovative drugs, providing an additional payment pathway beyond basic medical insurance [1] Group 2 - Zai Lab is in a rapid product expansion phase, with a rich pipeline of projects, and its clinical development of ZG006 is among the global leaders, potentially becoming the best in its class [2] - Zai Lab's self-developed drug, Jikangxi (sodium gikaxtin), has been included in the National Medical Insurance Drug Catalog following negotiations [2] - Junshi Biosciences has four commercialized products included in the 2025 National Medical Insurance Drug Catalog, with two new indications for Tuoyi (Tremelimumab) successfully added, and Junshida (Ongentys) being included for the first time [2]

Core Viewpoint - The 2025 National Medical Insurance Drug List has been announced, including 114 new drugs, with a focus on innovative drugs and significant improvements in coverage for key areas such as oncology and chronic diseases [4][9]. Group 1: Drug List Adjustments - The 2025 National Medical Insurance Drug List will be implemented on January 1, 2026, with a total of 3,253 drugs, including 1,857 Western medicines and 1,396 traditional Chinese medicines [4]. - The list includes 50 first-class innovative drugs and removes 29 drugs that are either not clinically available or can be replaced by better alternatives [4]. Group 2: Impact on A-Share Companies - 15 A-share pharmaceutical companies announced that their products were included in the new drug list, particularly benefiting innovative drug companies [6]. - Zai Lab's drug, Jikaxitinib, was included, which is used for treating specific types of myelofibrosis, enhancing its market accessibility and sales potential [6]. - Junshi Biosciences reported that its products, including Toripalimab and Oncorine, were added to the list, with all four of its commercialized products now covered [6]. Group 3: Major Pharmaceutical Companies - Leading A-share pharmaceutical companies like Fosun Pharma, Hengrui Medicine, and others have also had products included in the new list, with Hengrui having 10 drugs added and several others with new indications [7]. - Hengrui's drugs are projected to generate approximately 8.66 billion yuan in sales for 2024 and about 7.55 billion yuan for the first three quarters of 2025 [8]. Group 4: Complementary Innovations - In addition to the basic medical insurance list, 19 drugs have been added to the first version of the commercial insurance innovative drug list, including treatments for rare diseases and Alzheimer's, providing a complementary framework to the basic insurance [9].

Core Viewpoint - The 2025 National Medical Insurance Drug List has been released, adding 114 new drugs, including 50 innovative drugs, while removing 29 drugs that are no longer clinically available or can be replaced by better alternatives [2][5]. Group 1: New Additions to the Drug List - A total of 15 A-share pharmaceutical companies announced that their products have been included in the new drug list, particularly benefiting many innovative drug companies [5]. - Zai Lab's drug, Jikaxitinib, has been included in the National Medical Insurance Drug List, which is expected to enhance sales and improve patient accessibility [5][6]. - Junshi Biosciences has added two new indications for its drug, Toripalimab, and successfully included another drug, Oncorine, in the Class B category of the National Medical Insurance List [5]. Group 2: Impact on Major Pharmaceutical Companies - Leading A-share pharmaceutical companies such as Fosun Pharma, East China Pharmaceutical, and Hengrui Medicine have also had products included in the National Medical Insurance List [7]. - Hengrui Medicine has 10 drugs newly added to the list, with a total sales revenue of approximately 8.66 billion yuan in 2024 and about 7.55 billion yuan in the first three quarters of 2025 [8]. - The inclusion of these drugs in the National Medical Insurance List is expected to positively impact sales, although the exact effect on operating performance is currently uncertain [8]. Group 3: Overall Changes in the Drug List - The total number of drugs in the National Medical Insurance Drug List has increased to 3,253, with significant improvements in coverage for key areas such as cancer, chronic diseases, mental illnesses, rare diseases, and pediatric medications [2]. - This adjustment marks the 8th update since the establishment of the National Medical Insurance Bureau, indicating ongoing efforts to enhance drug accessibility and affordability [8].

Core Viewpoint - The 2025 National Medical Insurance Drug List has been released, including 114 new drugs, with a focus on innovative drugs and significant improvements in coverage for key areas such as cancer, chronic diseases, and rare diseases [4][5][10]. Group 1: New Drug Inclusion - A total of 15 A-share pharmaceutical companies announced that their products have been included in the new drug list, particularly benefiting innovative drug companies [7]. - Zai Lab's drug, Jikaxitinib, has been included in the list, which is expected to enhance sales and market accessibility for patients [7]. - Junshi Biosciences has multiple products included, with two new indications for its drug Toripalimab and another drug successfully included in the Class B category [7]. Group 2: Impact on Major Pharmaceutical Companies - Leading companies like Hengrui Medicine have had 10 products included in the new list, with an estimated combined sales of approximately 8.66 billion yuan for 2024 and about 7.55 billion yuan for the first three quarters of 2025 [9]. - Other major players such as Fosun Pharma and Huadong Medicine also have products included, indicating a broad impact across the industry [8]. Group 3: Overall Drug List Changes - The total number of drugs in the directory has increased to 3,253, with 1,857 Western medicines and 1,396 traditional Chinese medicines [5]. - The adjustment marks the eighth update since the establishment of the National Medical Insurance Bureau, reflecting ongoing efforts to enhance drug accessibility and affordability [10].